Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.68 |
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA4 | P22748 | 1/20 | 0.61 |
| ▸ | CA6 | P23280 | 1/20 | 0.61 |
| ▸ | CA5A | P35218 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5893459 | 0.94 | PTGS2 (0.72) | PTGS2CA1CA2CA12CA4 | |
| SCHEMBL8485289 | 0.87 | PTGS2 (0.70) | PTGS2 | |
| SCHEMBL8655486 | 0.82 | PTGS2 (1.00) | PTGS2 | |
| SCHEMBL8974092 | 0.82 | PTGS2 (0.63) | PTGS2CA1CA2CA12CA4 | |
| SCHEMBL8062129 | 0.82 | CA1 (0.56) | PTGS2CA1CA2CA12CA4 | |
| SCHEMBL23803137 | 0.82 | CA1 (0.57) | PTGS2CA1CA2CA12CA4 | |
| SCHEMBL1434498 | 0.82 | CA2 (0.64) | PTGS2CA1CA2CA12CA4 | |
| SCHEMBL13231429 | 0.80 | ENPP2 (0.54) | PTGS2CA1CA2CA12CA9 | |
| SCHEMBL156259 | 0.80 | CA2 (0.67) | PTGS2CA1CA2CA12CA4 | |
| Tetrabuthylammonium SCHEMBL29130219 | 0.80 | PTGS2 (0.49) | PTGS2CA1CA2CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874058-B | Mixed medicament and preparation method and application thereof | 杭州尚善若水环保科技有限公司 | 2023-12-15 | — | — | CN | claimed |
| CN-111205452-A | Phenolphthalein type high-dielectric polyarylether resin with side chain containing methylsulfonyl and preparation method thereof | 长安大学 | 2020-05-29 | — | — | CN | claimed |
| CN-111187406-A | Bisphenol acid type polyarylether dielectric material with side chain containing methylsulfonyl and preparation method thereof | 长安大学 | 2020-05-22 | — | — | CN | claimed |
| EP-2182950-B1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2017-07-19 | — | — | EP | claimed |
| US-9139567-B2 | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-22 | — | — | US | claimed |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-07 | — | — | US | claimed |
| CN-101675053-B | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH INC | 2014-03-12 | — | — | CN | claimed |
| CN-102827042-A | Chiral synthesis method of florfenicol | HUBEI MASTEAM BIO TECHNOLOGY CO LTD | 2012-12-19 | — | — | CN | claimed |
| CN-102548984-A | Inhibitors of PI3 kinase and / or MTOR | AMGEN INC | 2012-07-04 | — | — | CN | claimed |
| JP-4537315-B2 | — | — | 2010-09-01 | — | — | JP | claimed |
| US-7265152-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2007-09-04 | — | — | US | claimed |
| EP-1581207-A4 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1746888-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2007-01-31 | — | — | EP | claimed |
| JP-2006510736-A | — | — | 2006-03-30 | — | — | JP | claimed |
| WO-2005112640-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2005-12-01 | — | — | WO | claimed |
| EP-1581207-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-10-05 | — | — | EP | claimed |
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-23 | — | — | US | claimed |
| US-20050101623-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | US | claimed |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | claimed |
| WO-2004041201-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-05-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP4K2, MAP3K2 | PTGS2 703/4885CA1 2219/4885CA2 699/4885 |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | PTGS2 127/4885CA1 4081/4885CA2 3459/4885 |
| US-20050101623-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAP4K2, MAPKAPK2, MAP3K2 | PTGS2 893/4885CA1 3459/4885CA2 1109/4885 |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | BBOX1, HAVCR2, CYP2E1 | PTGS2 1053/4885CA1 4704/4885CA2 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.